Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online July 15, 2008
Diabetes 57:2801-2808, 2008
DOI: 10.2337/db07-1274
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-1274v1
57/10/2801    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Berti-Mattera, L. N.
Right arrow Articles by Mitchell, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berti-Mattera, L. N.
Right arrow Articles by Mitchell, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Sulfasalazine Blocks the Development of Tactile Allodynia in Diabetic Rats

Liliana N. Berti-Mattera1, Timothy S. Kern2,3, Ruth E. Siegel4, Ina Nemet1, and Rochanda Mitchell1

1 Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio
2 Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio
3 Veterans Administration Medical Center, Cleveland, Ohio
4 Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio

Corresponding author: Liliana N. Berti-Mattera, lnb{at}case.edu

OBJECTIVE—Diabetic neuropathy is manifested either by loss of nociception (painless syndrome) or by mechanical hyperalgesia and tactile allodynia (pain in response to nonpainful stimuli). While therapies with vasodilators or neurotrophins reverse some functional and metabolic abnormalities in diabetic nerves, they only partially ameliorate neuropathic pain. The reported link between nociception and targets of the anti-inflammatory drug sulfasalazine prompted us to investigate its effect on neuropathic pain in diabetes.

RESEARCH DESIGN AND METHODS—We examined the effects of sulfasalazine, salicylates, and the poly(ADP-ribose) polymerase-1 inhibitor PJ34 on altered nociception in streptozotocin-induced diabetic rats. We also evaluated the levels of sulfasalazine targets in sciatic nerves and dorsal root ganglia (DRG) of treated animals. Finally, we analyzed the development of tactile allodynia in diabetic mice lacking expression of the sulfasalazine target nuclear factor-{kappa}B (NF-{kappa}B) p50.

RESULTS—Sulfasalazine completely blocked the development of tactile allodynia in diabetic rats, whereas relatively minor effects were observed with other salicylates and PJ34. Along with the behavioral findings, sciatic nerves and DRG from sulfasalazine-treated diabetic rats displayed a decrease in NF-{kappa}B p50 expression compared with untreated diabetic animals. Importantly, the absence of tactile allodynia in diabetic NF-{kappa}B p50–/– mice supported a role for NF-{kappa}B in diabetic neuropathy. Sulfasalazine treatment also increased inosine levels in sciatic nerves of diabetic rats.

CONCLUSIONS—The complete inhibition of tactile allodynia in experimental diabetes by sulfasalazine may stem from its ability to regulate both NF-{kappa}B and inosine. Sulfasalazine might be useful in the treatment of nociceptive alterations in diabetic patients.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.